Chemistry/Biochemistry/Pharmacology Core
Chemistry/Biochemistry/Pharmacology Core
批准号:
10333993
负责人:
Spyros P Nikas
金额:
$36.21万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1994
资助国家:
美国
项目状态:
未结题
起止时间:
1994-09-30 至 2027-05-31
关键词:
2-arachidonylglycerolABHD6 geneActive SitesAddressAdenylate CyclaseAffinityAgonistAnimalsBindingBiochemistryBiological AssayBiological AvailabilityBrainCNR1 geneCNR2 geneCarrier ProteinsCellsCharacteristicsChemistryCollaborationsCyclic AMPDoctor of PhilosophyDrug KineticsEndocannabinoidsEnsureEnzymesEvaluationG-Protein-Coupled ReceptorsGlycerolGoalsGrantHumanHydrolaseIn VitroIndividualIon ChannelLaboratoriesLaboratory ResearchLettersLigandsLipaseLiverMeasuresMembraneMetabolicModelingMusPharmacodynamicsPharmacologyPlasmaPositioning AttributePreparationProgram Research Project GrantsPropertyRattusSecureSignal TransductionTestingWorkanaloganandamideantagonistcostendocannabinoid deactivating enzymefatty acid amide hydrolasein vivonovelpositive allosteric modulatorprogramsreceptorreceptor bindingscale upscreeningtherapeutic targettool
中文摘要
研究及相关-其他项目信息-项目摘要/摘要
这个核心B设施将作为一个技术和科学支助单位,为以下三个项目(1、2、3)提供支持
计划项目拨款。它的主要目标包括:(1)化合物的重新合成和放大
数量,以满足参与项目的研究实验室的体外和体内需求;
测试所有新的邻位配体对CB1和CB2大麻受体的亲和力;(3)测试
与CB1和CB2不可逆/紧密结合的能力;(4)测定官能团
CAMP分析中初始配基的性质(包括正构和变构);(5)二氨基苯甲酰胺的测试
类似物作为内源性大麻失活酶FAAH的底物;(6)
用肝微粒体和血浆制剂测定配体的代谢和血浆稳定性,
分别;(7)筛选针对G蛋白偶联受体的广泛的靶外相互作用,离子
通道、运输蛋白以及内源性大麻素代谢酶;以及(8)对选定的
一组新的配体在小鼠的中枢和血浆中的生物利用度;每一类的最佳候选者
广泛的药动学图谱。在核心B的支持下生产的化合物也将被
可供本计划项目中确定的其他实验室使用,这些实验室的合作不需要支付赠款费用。
英文摘要
RESEARCH & RELATED - OTHER PROJECT INFORMATION - PROJECT SUMMARY/ABSTRACT
This Core B facility will serve as a technical and scientific support unit for the three Projects (1, 2, 3) of this
Program Project Grant. Its major goals involve: (1) the re-synthesis and scale-up of compounds in sufficient
quantities to address the in vitro and in vivo needs of the research laboratories involved in the projects; (2) the
testing of all new orthosteric ligands for their affinities for the CB1 and CB2 cannabinoid receptors; (3) the testing
of orthosteric ligands for their abilities to bind irreversibly/tightly to CB1 and CB2; (4) determining the functional
properties of ligands initially in the cAMP assay (both orthosteric and allosteric); (5) the testing of anandamide
analogs for their abilities to act as substrates of the endocannabinoid deactivating enzyme, FAAH; (6)
determining the metabolic and plasma stabilities of ligands using liver microsomal and plasma preparations,
respectively; (7) screening for off-target interactions against a broad panel of G protein-coupled receptors, ion
channels, transport proteins as well as endocannabinoid metabolizing enzymes; and (8) evaluation of a select
group of novel ligands in mice for their bioavailability in CNS and plasma; the top candidates of each class in an
extensive pharmacokinetic profiling. Compounds produced under the auspices of Core B will also be made
available to other laboratories identified in this Program Project whose collaboration is at no cost to the grant.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Chemistry/Biochemistry/Pharmacology Core
-
批准号:10680369
-
项目类别:
-
资助金额:$36.55万
-
财政年份:1994
-
负责人:Spyros P Nikas
-
依托单位:
Core B Chemistry/Biochemistry/ Pharmacology Component
-
批准号:8742282
-
项目类别:
-
资助金额:$28.55万
-
财政年份:--
-
负责人:Spyros P Nikas
-
依托单位: